Valacyclovir 500 mg

Instructions for Valacyclovir 500 mg

Description
The pills are oval, biconvex, at risk, and covered with a film coating of white or almost white.

Release Form
Tablets

Composition Valacyclovir
1 tablet contains:

Active ingredient:
valacyclovir hydrochloride 556.20 mg in terms of valacyclovir 500.00 mg,

Auxiliary substances (kernel): corn starch 56.80 mg, silicon colloidal dioxide 2.00 mg, crosscarmellose sodium 29.00 mg, magnesium stearate 4.00 mg, microcrystalline cellulose (type 101) 72.00 mg,

Auxiliary substances (shell): Opadrai II white: 22.00 mg (macrogol (polyethylene glycol) 5.19 mg, polyvinyl alcohol 10.32 mg, talc 3.83 mg, titanium dioxide [E171] 2.66 mg).

Pharmacological effect Valacyclovir

Antiviral agent

Valacyclovir is an antiviral agent and is an L-valine ester of acyclovir. Acyclovir is an analog of the purine nucleoside (guanine).

Method of application and dose Valacyclovir

Inside, regardless of ingestion, tablets should be swallowed with water.

Treatment of skin and mucosal infections caused by HSV, including new-onset and recurrent genital herpes (Herpes genitalis) and labial herpes (Herpes labialis)
Immunocompetent adults and adolescents aged 12 to 18 years

The recommended dose is 500 mg twice a day.

Treatment should be continued for three or five days if relapses occur. For primary herpes, which may be more severe, treatment should be started as early as possible and increased from 5 days to 10 days. Relapsing HSV infections are best treated with the drug valacyclovir, given prodromally or immediately after symptoms appear. Valacyclovir, if given at the first sign and symptoms of HSV relapse, can help prevent disease.

Valacyclovir 2000 mg twice a day for 1 day is effective as an alternative treatment of labial herpes. The second dose should be taken about 12 hours (but not before 6 hours) after the first dose. When this dosing regimen is used, the duration of treatment should not exceed 1 day, because exceeding this course of treatment does not result in added clinical benefit.

Indications Valacyclovir

Use of the drug to treat herpes simplex virus (HSV) skin and mucous membrane infections, including primary and recurrent genital herpes (herpes genitalis) and lip herpes (herpes labialis) Use of the drug to prevent recurrence of skin and mucosal infections with HSV, including genital herpes, in adults with an impaired immune system. Preventing cytomegalovirus (CMV) infections and disorders after organ transplantation

pharmachologic effect Valacyclovir

After oral valacyclovir is absorbed well from the gastrointestinal tract and is rapidly and almost completely converted to acyclovir and valine. This transformation may be carried out by the liver enzyme valacyclovirhydrolase.
When valacyclovir 1000 mg is given, the bioavailability of acyclovir is 54% and is independent of meals. The pharmacokinetics of valacyclovir do not change with dosage. The rate and degree of absorption decrease with increasing dose, resulting in a less proportionate increase in maximum plasma concentration (Cmax) than in therapeutic doses and decreased bioavailability for doses above 500 mg.